Positive early safety and efficacy data with nomacopan Phase II clinical study in patients with mild-to-moderate bullous pemphigoid (BP) announced April …

[Read more...] about Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress

NEW YORK and LONDON, July 31, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat …

[Read more...] about Akari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with Bullous Pemphigoid at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, 2019